A Phase 2 Multicenter, Investigator-Blind, Subject-Blind, Placebo-Controlled Study of the Efficacy, Safety, and Pharmacokinetics of Bimekizumab in Subjects With Moderate to Severe Hidradenitis Suppurativa
Phase of Trial: Phase II
Latest Information Update: 03 Mar 2018
At a glance
- Drugs Bimekizumab (Primary) ; Adalimumab
- Indications Hidradenitis suppurativa
- Focus Therapeutic Use
- Sponsors UCB Biopharma
- 16 Oct 2017 Status changed from not yet recruiting to recruiting.
- 18 Sep 2017 Planned End Date changed from 2 Jan 2019 to 12 Feb 2019.
- 18 Sep 2017 Planned primary completion date changed from 2 Jan 2019 to 12 Feb 2019.